EU OKs Liraglutide in Kids; Rejects Romosozumab for Osteoporosis EU OKs Liraglutide in Kids; Rejects Romosozumab for Osteoporosis
The CHMP recommended approval of the GLP-1 agonist liraglutide for type 2 diabetes in children aged 10 and older, but it recommended refusal of marketing authorization for osteoporosis agent romosozumab.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Children | Diabetes | Diabetes Type 2 | Endocrinology | Health | Marketing | Orthopaedics | Osteoporosis | Victoza